 Connection
Barry Uretsky to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Barry Uretsky has written about Angiotensin-Converting Enzyme Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.583 |
|
|
|
-
Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryd?n L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999 Dec 07; 100(23):2312-8.
Score: 0.169
-
Aleti S, Bansal D, Agrawal M, Uretsky BF, Sachdeva R. Effect of chronic angiotensin converting enzyme inhibitor therapy on myocardial injury in patients undergoing percutaneous coronary interventions. J Invasive Cardiol. 2011 Feb; 23(2):72-5.
Score: 0.092
-
Uretsky BF, Shaver JA, Liang CS, Amin D, Shah PK, Levine TB, Walinsky P, LeJemtel T, Linnemaier T. Lisinopril for severe congestive heart failure. Am J Cardiol. 1989 Feb 21; 63(8):8D-11D.
Score: 0.080
-
Uretsky BF, Shaver JA, Liang CS, Amin D, Shah PK, Levine TB, Walinsky P, LeJemtel T, Linnemeier T, Rush JE, et al. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. Am Heart J. 1988 Aug; 116(2 Pt 1):480-8.
Score: 0.077
-
Cleland JG, Thygesen K, Uretsky BF, Armstrong P, Horowitz JD, Massie B, Packer M, Poole-Wilson PA, Ryd?n L. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J. 2001 Sep; 22(17):1601-12.
Score: 0.048
-
Young JB, Gheorghiade M, Uretsky BF, Patterson JH, Adams KF. Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. J Am Coll Cardiol. 1998 Sep; 32(3):686-92.
Score: 0.039
-
Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol. 1997 Dec; 30(7):1589-97.
Score: 0.037
-
Stone CK, Uretsky BF, Linnemeier TJ, Shah PK, Amin DK, Snapinn SM, Rush JE, Langend?rfer A, Liang CS. Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. Am J Cardiol. 1989 Mar 01; 63(9):567-70.
Score: 0.020
-
Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JG, Massie BM, Ryd?n L. Mode of death in heart failure: findings from the ATLAS trial. Heart. 2003 Jan; 89(1):42-8.
Score: 0.013
-
Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997 Jul; 134(1):44-54.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|